Trials / Unknown
UnknownNCT05410847
Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
A Prospective Study of Intraperitoneal and Intravenous Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hebei Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous nab-paclitaxel plus Camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab Nab-Paclitaxel S-1 | Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel |
Timeline
- Start date
- 2022-06-30
- Primary completion
- 2023-06-30
- Completion
- 2025-06-30
- First posted
- 2022-06-08
- Last updated
- 2022-06-24
Source: ClinicalTrials.gov record NCT05410847. Inclusion in this directory is not an endorsement.